# Roivant Sciences Ltd.: filings

ROIV · Nasdaq · CIK 1635088 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/roiv.md) · [Financials](/companies/roiv/financials.md) · [Filings](/companies/roiv/filings.md) · [Insiders](/companies/roiv/insiders.md)

## Reports and events: 145 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 463, 144 180, 8-K 79, 3 30, SC 13D/A 26, 424B3 20, SC 13G/A 19, 10-Q 16, SCHEDULE 13G/A 16, CORRESP 10, EFFECT 10, 425 9, SC 13G 9, 424B5 8, UPLOAD 7, 10-K 5, 144/A 5, DEF 14A 5, DEFA14A 5, S-8 5, ARS 4, POS AM 4, S-4/A 4, SC 13D 4, 8-K/A 3, S-1 3, SCHEDULE 13D/A 3, S-3 2, SEC STAFF LETTER 2, 25-NSE 1, 424B7 1, 8-A12B 1, 8-A12B/A 1, CERT 1, S-1/A 1, S-3ASR 1, S-4 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-21 | 07:05 ET | [8-K](/filings/0001140361-26-040332.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-040332 |
| 2026-10-05 | 21:02 ET | [SCHEDULE 13D/A](/filings/0001140361-26-038693.md) | Ownership report, active investor, amended | 0001140361-26-038693 |
| 2026-09-18 | 07:14 ET | [8-K](/filings/0001635088-26-000095.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001635088-26-000095 |
| 2026-09-08 | 09:15 ET | [8-K](/filings/0001140361-26-035859.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-035859 |
| 2026-08-28 | 16:31 ET | [8-K](/filings/0001140361-26-034854.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-034854 |
| 2026-08-27 | 17:24 ET | [8-K](/filings/0001140361-26-034735.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-034735 |
| 2026-08-06 | 07:28 ET | [10-Q](/filings/0001635088-26-000090.md) | Quarterly report, period 2026-06-30 | 0001635088-26-000090 |
| 2026-08-06 | 07:13 ET | [8-K](/filings/0001635088-26-000088.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001635088-26-000088 |
| 2026-07-29 | 07:00 ET | [DEF 14A](/filings/0001140361-26-029955.md) | Proxy statement, period 2026-09-16 | 0001140361-26-029955 |
| 2026-05-20 | 07:17 ET | [10-K](/filings/0001635088-26-000061.md) | Annual report, period 2026-03-31 | 0001635088-26-000061 |
| 2026-05-20 | 07:14 ET | [8-K](/filings/0001635088-26-000060.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001635088-26-000060 |
| 2026-04-02 | 07:00 ET | [8-K](/filings/0001140361-26-012885.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-012885 |
| 2026-03-23 | 08:44 ET | [8-K/A](/filings/0001140361-26-010656.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-26-010656 |
| 2026-03-03 | 16:15 ET | [8-K](/filings/0001140361-26-007548.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-007548 |
| 2026-03-03 | 07:13 ET | [8-K](/filings/0001140361-26-007447.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-007447 |
| 2026-02-06 | 07:31 ET | [10-Q](/filings/0001635088-26-000011.md) | Quarterly report, period 2025-12-31 | 0001635088-26-000011 |
| 2026-02-06 | 07:12 ET | [8-K](/filings/0001635088-26-000009.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001635088-26-000009 |
| 2025-12-11 | 07:46 ET | [8-K](/filings/0001140361-25-045204.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-25-045204 |
| 2025-11-10 | 07:25 ET | [10-Q](/filings/0001635088-25-000016.md) | Quarterly report, period 2025-09-30 | 0001635088-25-000016 |
| 2025-11-10 | 07:21 ET | [8-K](/filings/0001140361-25-041269.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-25-041269 |
| 2025-09-17 | 07:45 ET | [8-K](/filings/0001140361-25-035190.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-035190 |
| 2025-09-11 | 17:00 ET | [8-K](/filings/0001140361-25-034711.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001140361-25-034711 |
| 2025-09-03 | 13:38 ET | [8-K](/filings/0001140361-25-033767.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-033767 |
| 2025-08-11 | 07:31 ET | [10-Q](/filings/0001140361-25-030001.md) | Quarterly report, period 2025-06-30 | 0001140361-25-030001 |
| 2025-08-11 | 07:17 ET | [8-K](/filings/0001140361-25-029998.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-25-029998 |
| 2025-07-29 | 16:58 ET | [DEF 14A](/filings/0001140361-25-027846.md) | Proxy statement, period 2025-09-10 | 0001140361-25-027846 |
| 2025-06-25 | 07:32 ET | [8-K](/filings/0001140361-25-023553.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-023553 |
| 2025-05-29 | 07:53 ET | [10-K](/filings/0001140361-25-020715.md) | Annual report, period 2025-03-31 | 0001140361-25-020715 |
| 2025-05-29 | 07:33 ET | [8-K](/filings/0001140361-25-020713.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-25-020713 |
| 2025-04-21 | 07:42 ET | [8-K](/filings/0001140361-25-014642.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-25-014642 |
| 2025-03-20 | 16:30 ET | [8-K](/filings/0001140361-25-009696.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-25-009696 |
| 2025-03-19 | 07:51 ET | [8-K](/filings/0001140361-25-009362.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-009362 |
| 2025-02-25 | 07:19 ET | [SCHEDULE 13D/A](/filings/0001140361-25-005770.md) | Ownership report, active investor, amended | 0001140361-25-005770 |
| 2025-02-21 | 16:45 ET | [8-K](/filings/0001140361-25-005445.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-25-005445 |
| 2025-02-18 | 17:21 ET | [SCHEDULE 13D/A](/filings/0001140361-25-005025.md) | Ownership report, active investor, amended | 0001140361-25-005025 |
| 2025-02-10 | 10:16 ET | [10-Q](/filings/0001140361-25-003661.md) | Quarterly report, period 2024-12-31 | 0001140361-25-003661 |
| 2025-02-10 | 07:15 ET | [8-K](/filings/0001140361-25-003639.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-25-003639 |
| 2024-12-03 | 07:20 ET | [8-K](/filings/0001140361-24-048238.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-24-048238 |
| 2024-11-12 | 07:30 ET | [10-Q](/filings/0001140361-24-046019.md) | Quarterly report, period 2024-09-30 | 0001140361-24-046019 |
| 2024-11-12 | 07:22 ET | [8-K](/filings/0001140361-24-046015.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-24-046015 |
| 2024-10-28 | 16:30 ET | [8-K](/filings/0001140361-24-044434.md) | 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-24-044434 |
| 2024-09-23 | 16:34 ET | [8-K](/filings/0001140361-24-041663.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-24-041663 |
| 2024-09-18 | 07:40 ET | [8-K](/filings/0001140361-24-041344.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-24-041344 |
| 2024-09-16 | 17:05 ET | [8-K](/filings/0001140361-24-041188.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001140361-24-041188 |
| 2024-09-10 | 07:15 ET | [8-K](/filings/0001140361-24-040650.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-24-040650 |
| 2024-09-09 | 07:53 ET | [8-K](/filings/0001140361-24-040507.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-24-040507 |
| 2024-08-09 | 16:32 ET | [10-Q](/filings/0001140361-24-036642.md) | Quarterly report, period 2024-06-30 | 0001140361-24-036642 |
| 2024-08-08 | 07:15 ET | [8-K](/filings/0001140361-24-036281.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-24-036281 |
| 2024-07-26 | 16:59 ET | [DEF 14A](/filings/0001140361-24-034423.md) | Proxy statement, period 2024-09-10 | 0001140361-24-034423 |
| 2024-05-30 | 16:46 ET | [10-K](/filings/0001140361-24-028145.md) | Annual report, period 2024-03-31 | 0001140361-24-028145 |

Page 1 of 3. [Older](/companies/roiv/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 18:30 ET. No prices; not investment advice.